Mr. Denise Faltischek reports

TILRAY MEDICAL LAUNCHES ITS FIRST COMMERCIAL "GROWN IN GERMANY" MEDICAL CANNABIS PRODUCTS UNDER ITS NEWLY EXPANDED CULTIVATION LICENSE

Tilray Brands Inc. has launched its first commercial German-grown medical cannabis flowers from its Aphria RX GmbH facility. This launch marks the first medical cannabis products to be grown in Germany by Aphria RX under the newly issued medical cannabis cultivation licence under MedCanG.

On July 15, 2024, Tilray Medical was the first to receive a new cannabis cultivation licence issued under MedCanG. This licence allows Aphria RX to cultivate and manufacture a broad range of commercially available medical cannabis in Germany. The strains to be grown at this indoor facility have been carefully selected from top performing varieties popular with patients across Canada.

Tilray's chief strategy officer and head of international, Denise Faltischek, said: "We are excited to launch our made-in-Germany premium cannabis products, which marks a significant milestone in our mission to deliver the highest-quality medical cannabis products to patients in Germany. This not only serves to expand Tilray's leadership in medical cannabis cultivation, production and distribution in Germany but also proves our commitment to be one of the most responsible, trusted and market-leading cannabis companies in the world with a portfolio of innovative and high-quality products that address the needs of patients. We reiterate our appreciation for the trust that the German government has placed in Tilray and we are proud of our Aphria RX team for their groundbreaking work in medical cannabis cultivation and patient care."

About Tilray Brands Inc.

Tilray Brands is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness and entertainment, elevating lives through moments of connection.

We seek Safe Harbor.